Axonyx Phase II AD data

AXYX said that in a Phase II study of 72 patients with mild-to-moderate Alzheimer's disease (AD) its Phenserine acetylcholinesterase inhibitor improved ADAS-cog (a measure of cognitive function) compared to placebo, the primary endpoint, but the difference was not statistically significant (p=0.147). AXYX said that the trial was not powered to detect significance on the primary endpoint. "The study was designed to look at the therapeutic window of the compound," said AXYX CEO Marvin Hausman. "We also decided to look at multiple cognitive parameters, although the trial was not powered" to detect significance on these measures. ...